Search Results for "Alnylam"
Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.
More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.
For more information about our FDA-approved therapies, please see the Full Prescribing Information:
Patisiran: Use in Patients Undergoing Dialysis
Standard response letter on patisiran and dialysis. This medical information response contains clinical pharmacology data about patisiran and safety data from the Phase 2 OLE, APOLLO, and Global OLE studies.
Standard response letter on patisiran and dialysis. This medical information response contains clinical pharmacology data about patisiran and safety data from the Phase 2 OLE, APOLLO, and Global OLE studies.
Vutrisiran: Arthralgia
Standard response letter on vutrisiran and the adverse event of arthralgia.
Standard response letter on vutrisiran and the adverse event of arthralgia.
Lumasiran: ILLUMINATE-A Study Overview
Standard response letter on the lumasiran phase 3 clinical study ILLUMINATE-A. This medical information response contains information on the 6-month double-blinded treatment period and through 36 months of the open-label extension.
Standard response letter on the lumasiran phase 3 clinical study ILLUMINATE-A. This medical information response contains information on the 6-month double-blinded treatment period and through 36 months of the open-label extension.
Patisiran: Orthostatic Hypotension
Standard response letter on the effect of patisiran on orthostatic hypotension in the APOLLO, Global OLE, and HELIOS-A studies.
Standard response letter on the effect of patisiran on orthostatic hypotension in the APOLLO, Global OLE, and HELIOS-A studies.
Patisiran: Serum Transthyretin Levels
Standard response letter on patisiran and changes in serum TTR levels observed in the Phase 2 OLE, APOLLO, APOLLO-B, and HELIOS-A studies.
Standard response letter on patisiran and changes in serum TTR levels observed in the Phase 2 OLE, APOLLO, APOLLO-B, and HELIOS-A studies.
Vutrisiran: HELIOS-B
Standard response letter on vutrisiran and the HELIOS-B study, a phase 3 study evaluating the efficacy and safety of vutrisiran in patients with the cardiomyopathy of ATTR, including both hATTR and wtATTR.
Standard response letter on vutrisiran and the HELIOS-B study, a phase 3 study evaluating the efficacy and safety of vutrisiran in patients with the cardiomyopathy of ATTR, including both hATTR and wtATTR.
Lumasiran: Stability in Prepared Syringe
Standard response letter on the stability of lumasiran in a prepared syringe.
Standard response letter on the stability of lumasiran in a prepared syringe.
Vutrisiran: Drug Interactions
Standard response letter on vutrisiran and drug interactions.
Standard response letter on vutrisiran and drug interactions.
Vutrisiran: Dosage & Administration Schedule Used in Phase 3 Studies
Standard response letter on the dosing schedules of vutrisiran used in the HELIOS-A and HELIOS-B studies.
Standard response letter on the dosing schedules of vutrisiran used in the HELIOS-A and HELIOS-B studies.
Zilebesiran: Phase 2 Studies
Standard response letter on zilebesiran and the phase 2 studies: KARDIA-1, KARDIA-2, and KARDIA-3.
Standard response letter on zilebesiran and the phase 2 studies: KARDIA-1, KARDIA-2, and KARDIA-3.
